PBX-004 / PinotBio - LARVOL DELTA

A novel Integrin beta-6-targeted antibody-drug conjugate featuring a topoisomerase I inhibitor, PBX-004 with potent antitumor activity in multiple preclinical solid tumor models (AACR-NCI-EORTC 2025) - "The anti-tumor activity of PBX-004 was comparable to, or exceeded, that of the MMAE-based ADC Sigvotatug Vedotin (SGN-B6A; Pfizer/Seagen) at equivalent dose levels. Enhanced efficacy is anticipated through a next-generation antibody and the novel PBX-7016 payload. PBX-004 may overcome the limitations of MMAE-based ADCs and offer a superior option for patients with various integrin beta-6–expressing solid tumors, including NSCLC, HNSCC, and TNBC."

Preclinical • Breast Cancer • Cervical Cancer • Colorectal Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ITGB6 • TOP1